LogicBio Therapeutics (NASDAQ: LOGC) reported Q2 EPS of ($0.14), $0.10 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $33.6 million.

For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.